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Oral Presentations 21develop symptom burden that substantially interferes with daily ac-
tivities. Acute graft-versus-host disease (aGVHD) may significantly
contribute to symptom burden.
Theoretical Framework: Symptom burden is the combined
impact of all symptoms on one’s ability to function as one did before
onset of disease and therapy.
Problem and Purpose: Symptom burden cannot be managed if it
is not reliably and sensitively measured over time. The purpose of
this study was to determine the reliability and sensitivity of the M.
D. Anderson Symptom Inventory (MDASI), a brief self-report
measure of the severity and impact of cancer-related symptoms, in
patients with and without aGVHD.
Methods: This is a retrospective analysis of a combined dataset of
125 patients who had completed multiple assessments using the
MDASIduring thefirst3months following alloHSCT.Symptombur-
denwasmeasuredusing the areaunder the curve (AUC)ofmeansymp-
tom severity scores from day of HSCT to 3 months after HSCT.
Results: Sample demographic, disease, and HSCT characteristics
andmean and standard deviations (SD) of symptom severity at 3 time
points are in shown Table 1. The MDASI symptom items had
a reliability index (Cronbach alpha) of 0.892. The MDASI symptom
items were sensitive enough to detect a significant difference in the
AUC of symptom severity from the day of HSCT to 3 months after
HSCT (p 5 0.025) and from 22 days to 3 months after HSCT (p 5
0.031) between patients with and without aGVHD.
Implications: The difference in symptom burden between
patients with and without aGVHD was not significant from the
day of HSCT to 22 days after HSCT.We had predicted that the dif-
ference would not be significant between the 2 groups during this
time period, as symptoms during this time are caused mainly by
the preparative regimen. We had predicted that the difference in
symptom severity would be greater between patients with and with-
out aGHVDbetween 22 and 100 days afterHSCT. ByDay 22, many
patients will have engrafted and aGVHD will begin to develop and
increase symptom burden. The MDASI is an easily-completed and
reliable measure of symptom burden in patients undergoing
alloHSCT and is sensitive enough to detect differences in symptom
burden between patients with and without aGVHD.
Table 1. Demographic/Treatment Characteristics and Symp-
tom Severity Means
N5125 N %Sex - Male 67 53.6%
Race - White, non-Hispanic 85 68.0%
Diagnosis
Acute leukemia/MDS 77 61.6%
Chronic leukemia 19 15.2%
Lymphoma 22 17.6%
Other 7 5.6%Type of HSCT
Related donor 94 75.2%
Unrelated donor 31 24.8%Maximum Grade of aGVHD
None 54 43.2%
1 35 28.0%
2 19 15.2%
3 17 13.6%
4 0 0Mean SD1Age 41.12 12.95
Highest Grade of
School Completed14.68 2.06No aGVHD aGVHD No aGVHD aGVHD
Mean Symptom
Severity Score - Day
of HSCT22.80 2.63 1.82 1.88Mean Symptom
Severity Score - Day 2222.21 2.66 1.78 1.87Mean Symptom
Severity Score - 3 Months21.43 2.36 1.35 1.791SD 5 standard deviation.
2Symptom severity: 0 to 10 scale, 05 not present 105 as bad as you can
imagine.LEUKEMIA
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IMPACT OF CYTOGENETICS RISK ON OUTCOME AFTER REDUCED INTEN-
SITY CONDITIONING (RIC) ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLO-SCT) FROM AN HLA IDENTICAL SIBLING FOR PATIENTS WITH
ACUTE MYELOID LEUKEMIA (AML) IN FIRST COMPLETE REMISSION
(CR1)
Mohty, M., Labopin, M., Milpied, N., Cornelissen, J.J., Blaise, D.,
Petersen, E., Theorin, N., Goker, H., Socie, G., Rocha, V., for the Acute
Leukemia Working Party of EBMT, Paris, France
The relatively higher risk of relapse after RIC allo-SCT, and con-
tinuous improvements in non-allo-SCT strategies, raise concern
about the utility of this approach in AML patients in CR1 (e.g. in
comparison to intensive chemotherapy and new drugs). Thus far,
no large studies have yet assessed the impact of cytogenetics risk on
outcome after RIC allo-SCT. This report describes the results of
378 AML patients transplanted in CR1 using a RIC regimen and re-
ported to the EBMT registry between 2000 and 2007, and for whom
detailed cytogenetics data were available. All patients received RIC
allo-SCTfromanHLA identical sibling.RICwasdefinedasBusulfan
conditioning regimens containing\ 8mg/kg total dose, or TBI\6
Gy: The median age was 55 (range, 18–74) y. The median intervals
from AML diagnosis to CR1 and from CR1 to RIC allo-SCT were
45 and 155 days respectively. In this series, 21 patients (6%) were in
the good cytogenetics risk group,while 304 patients (80%) and 53 pa-
tients (14%) belonged to the intermediate and poor cytogenetics risk
groups respectively. Age, year of transplant, WBC at diagnosis, gen-
der, CMV serostatus, stem cell source, and RIC regimen type were
comparable between all three groups. The M5-6-7 FAB subgroup
was significantly higher in the poor risk group (30% vs. 20% in the
intermediate group). With a median follow-up of 24 (range, 1–93)
months, the KM estimates of 2 years leukemia-free survival (LFS)
were 6464, 5763 and 3867% in the good-, intermediate-, and
poor-risk subgroups respectively (P 5 0.003). In multivariate analy-
sis, cytogenetics was not significantly associated with non-relapse
mortality. However, relapse incidence was significantly influenced
by the cytogenetics risk groups (P5 0.0001) and a higherWBCat di-
agnosis (P5 0.001). Finally, LFS was significantly influenced by the
cytogenetics risk groups (P5 0.004), a higherWBCat diagnosis (P5
0.006), and year of transplant (P 5 0.04). These results suggest that
RIC allo-SCT from anHLA-matched sibling donor is a valid option
for AMLpatients inCR1 not eligible for standard allo-SCT.As it has
been shown in the setting of myeloablative conditioning allo-SCT,
patients from the poor cytogenetics risk group had increased relapse
incidence and decreased LFS rate after RIC allo-SCT. Therefore,
prospective strategies such as use of new drugs, intensification of
conditioning regimen, post-transplant immunotherapy should be
investigate to improve current results in this group.51
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PBPC is an acceptable alternative to bone marrow (BM) for trans-
planting children with leukemia. Children and adolescents with leu-
kemia receiving PBSC compared to BM fromHLA-identical sibling
donors had more chronic graft-vs-host disease (GVHD), higher
transplant-relatedmortality (TRM) and lower leukemia-free survival
(LFS). We wanted to find out if children receiving unrelated donor
grafts should be given BM rather than PBPC. Therefore, we com-
pared the results of 385 unrelated donor BM transplants that were
allele-matched (n 5 186) or mismatched (n 5 199) at HLA A, B,
C, DRß1 and 110 PBPC transplants that were matched (n 5 60)
or mismatched (n 5 50) at HLA A, B, C, DRß1 in patients younger
22 Oral Presentationsthan 18 years of age. All patients had acute leukemia and were trans-
planted in 2000–2006. Median follow-up of surviving patients was 2
years in both treatment groups. There were no significant differences
in patient and disease characteristics, transplant conditioning
regimen, GVHD prophylaxis and donor-recipient HLA disparity
by graft type. Though the early probability of neutrophil recovery
($500/ul) was faster after transplantation of PBPC (31% vs. 10%
at day-14, p\0.001) the probability of recovery by day-28was similar
after PBPC and BM transplants (94% and 91%, p5 0.391). Platelet
recovery ($20,000/ul) was better after PBPC transplants (86% vs.
76% at day-60, p 5 0.022). Risks of grade 2–4 (hazard ratio [HR]
1.24, p 5 0.147) and grade 3–4 (HR 1.07, p 5 0.785) acute
GVHDwere similar after PBPC and BM transplants. The risk of de-
veloping chronic GVHDwas significantly greater after PBPC trans-
plants compared to BM transplants (HR 2.36, p\0.001). After
adjusting for disease status, donor-recipient HLA disparity and
age, TRM, relapse, leukemia-free survival and overall survival were
similar after PBPC and BM transplants. In parentheses is shown
the day-100 probability of grade 2–4 acute GVHD (53%/49%) the
3-year probabilities of chronic GVHD (58%/33%), TRM (20%/
24%), relapse (34%/28%), LFS (46%/48%) and overall survival
(49%/49%) for the PBPC/BM groups, respectively. These results
differ from transplantation of PBPC from HLA-matched siblings
To conclude, in patients \18 years of age with acute leukemia,
unrelated PBPC transplant compared to BM resulted in faster recov-
ery of neutrophils and platelets and an increased risk of chronic
GVHD. Acute GVHD, TRM, relapse, survival and LFS were
similar using PBPC or BM.LYMPHOMA/MULTIPLE MYELOMA
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COMPLETE TUMOR RESPONSES IN LYMPHOMA PATIENTSWHO RECEIVE
AUTOLOGOUS CYTOTOXIC T LYMPHOCYTES TARGETING EBV LATENT
MEMBRANE PROTEINS
Bollard, C.M., Stanojevic, M., Leen, A.M., Lopez, T., Sheehan, A.,
Carrum, G., Liu, H., Chang, C.-C., Gee, A.P., Brenner, M.K.,
Rooney, C.M., Heslop, H.E., Gottschalk, S.M. Baylor College of Medicine,
Houston, TX
EBV-associated Hodgkin’s Lymphoma (HL) and some non-
Hodgkins lymphoma (NHL) have type II viral latency expressing
the subdominant EBV antigens EBNA1, LMP1 and LMP2. These
antigens may serve as targets for immunotherapy approaches after
stem cell transplant. We hypothesized that CTL enriched for effec-
tor cells specifically targeting LMP antigens would have efficacy in
HL and NHL patients. LMP-CTL were generated using dendritic
cells for initial stimulations then EBV-transformed lymphoblastoid
cell lines (LCL) both of which had been geneticallymodified to over-
express either LMP2 alone or inactive LMP1 (DLMP1) and LMP2
by transduction with an Ad5f35LMP2 (n 5 16) or Ad5f35DLMP1-
I-LMP2 (n5 14) vector respectively. All LMP-CTL lines were poly-
clonal comprising CD41 (mean 17618%; range 1–92) and CD81
(mean 74 6 25%; range 1–99) T-cells. Flow cytometric analysis of
memory markers revealed mixed populations of CD45RA-
CD62L- T-cells (45615%; range 31–63) and CD45RA- CD62L1
T-cells (3465%; range 28–41). The CTL lines had specificity for
CD41 and CD81 restricted LMP2 epitopes alone (n 5 19; mean
1; range 0–7) or both LMP1 and LMP2 epitopes (n 5 13; mean 2;
range 0–6) per CTL line, as determined using overlapping LMP1
and LMP2 peptide pools in ELISPOT assays. 24 patients with
EBV1 HL and NHL have been treated on dose escalation studies.
16 with LMP2 CTLs and 8 with LMP1/2 CTLs. No immediate
toxicity was observed. After CTL infusion, increased numbers of
LMP-specific T cells were detected in the blood of 15/22 evaluable
patients, (range 2 to 70 fold) persisting for up to 3 months. Addition-
ally, two patients had lymph node biopsies 3–6 months post CTL,
which showed selective accumulation of LMP2-multimer positive
cells in lymph nodes. 12/13 high-risk and/or multiply relapsed pa-
tients who received LMP-CTL as adjuvant treatment after SCT or
chemotherapy remained in remission for a median of 2yrs (range
. 3mths to 5years) after CTL. 11 patients had detectable disease
at the time of CTL, 2 of these had progressive disease by 8 wks
and 9 had clinical responses. The median duration of the clinical
responses is 1 yr with one stable disease (.12months), one partialresponse (36 months), and 7 complete responses (range 9 months
to .4.5 years). In conclusion, immunotherapy with CTL targeting
LMP antigens is well tolerated in patients with EBV1 lymphoma
and infused LMP-CTL can accumulate at tumor sites and induce
complete and sustained clinical responses.53
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(CTCL): A RETROSPECTIVE ANALYSIS OF THE LYMPHOMA WORKING
PARTY OF THE EUROPEAN BLOOD AND MARROW TRANSPLANTATION
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Patients with advanced stageMycosis Fungoides (MF), Sezary syn-
drome (SS) and other less common subtypes of primary CTCL have
a dismal prognosis with conventional therapy. A potential role for
alloSCT in these patients has been suggested by a small number of
case-reports and small series.Wehave now conducted a retrospective
registry analysis of 64 recipients of an alloSCT from HLA-Identical
donors (52 related, 12 unrelated) for advanced CTCL reported to
EBMTbetween 1997 and 2006: 23MF, 21 SS, 16 primary cutaneous
anaplastic large cell lymphoma and 4 subcutaneous panniculitis-like
T-cell lymphoma; 38 male/26 female; median age 46 (5–65); median
follow up in survivors, 28 months). AlloSCTwas performed at a me-
dian of 22 (3–313) months from initial diagnosis, following a median
of 3 (1–8) prior lines of therapy, 54 PB and 10 BMas stem cell source,
and using a reduced-intensity conditioning (RIC) in 41 (64%) cases.
Only 23% of patients were in CR and 26% in PR at the time of al-
loSCT.The restwereprimary refractory (RE, 25%)or inprogression
(PG, 26%). Non-relapse mortality was 24% at 3 years, and appeared
poorer in patients receiving myeloablative conditioning (MAC) than
in those receiving RIC alloSCT (35% vs 16%; p5 0.06). Acute graft
versus host disease (GVHD) occurred in 37% of patients at risk, and
chronicGVHDin 69%of patients alive at day1100.The cumulative
incidence of disease relapse (36% at 3 years) was significantly higher
in patients with advanced disease status at alloSCT (RE/PG 46% vs
CR/PR 21%; p 5 0.01), but similar between related and unrelated
donors (p5 0.39) and between MAC and RIC (p5 0.58). First pro-
gression free survival (PFS) at 3 years was 41%, with a significant ad-
vantage for patients inCR/PRat alloSCT (58%vs 26%; p\0.01), but
not for type of conditioning (MAC 45% vs RIC 44%; p 5 0.44) or
donor type (related 46% vs unrelated 33%; p5 0.17). Out of 22 pa-
tients who relapsed, 10 remain alive and 4 of these are in CR at last
followup, indicating that a proportion of patients can achieve a better
control of their CTCL following relapse after alloSCT. Overall sur-
vival for the whole series was 55% at 3 years, with a trend towards an
improved OS for patients with disease in CR/PR at transplant (65%
vs 46%; p 5 0.12). Overall, this outcome appears superior to the
expected median OS for these patients with conventional therapy,
and reinforces, in the largest series to date, the important role of
alloSCT in advanced stage CTCL.54
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Autologous hematopoietic cell transplantation (auto HCT) is ef-
fective therapy for patients with advanced Hodgkin (HL) and non-
